
Agreement - April 6, 2022
Idogen signs agreement with two Nordic CROs
Idogen has signed a strategic collaboration agreement with two contract research organizations, Danish Klifo and Finnish 4Pharma, which will together with Idogen run the clinical phase 1/2a study with IDO 8. IDO 8 is a new cell therapy for patients with severe hemophilia who have developed antibodies to their treatment with coagulation factor VIII. The […]

Pharma Business - March 3, 2020
Idogen publishes prospectus in connection with the forthcoming rights issue
The Board of Directors of Idogen has, due to the company’s forthcoming rights issue that was announced on January 28, 2020, prepared an EU Growth Prospectus which now has been approved and registered by the Swedish Financial Supervisory Authority. “The forthcoming Rights Issue has the potential to strengthen Idogen’s capabilitiy to become a successful and […]

Drug Development Pharma - January 20, 2020
Idogen’s cell technology advanced to large-scale production
Idogen has announced that the company’s technology platform for tolerogenic dendritic cell generation has been successfully advanced from pilot to production-scale. Results from completed tests show that the technology platform can now generate functional cells in considerably larger volumes than previously possible, states the company. As the next step, Idogen now initiates the partnership with […]

In a new job - August 13, 2019
Idogen appoints a new CEO
Anders Karlsson has been appointed new CEO for the company and he will take up his new position on August 19, 2019. Anders Karlsson has a broad experience from a range of pharma and medtech companies, including leading positions at Novartis and Olerup International. ”Idogen has ground-breaking development projects within immunology and transplantation, areas which […]

Intellectual Property - December 14, 2017
Idogen has been granted a patent in the USA
The United States Patent & Trademark Office has granted a patent covering the company’s technology for tolerogenic immune therapy. This technology forms the basis of the new therapies developed by Idogen to prevent the immune system from disabling the standard treatment of hemophilia, as well as causing rejection of transplanted organs. Patents in the same […]

In a new job - March 31, 2017
Idogen recruits new CMO
Idogen has recruited Dr. Steven Glazer to the position of Chief Medical Officer (CMO) commencing the 1st of April. The company hopes that this appointment means a strengthening of the organization for future clinical studies, initially in hemophilia A. “I look forward to working with Idogen and hemophilia again – a patient group I’ve worked […]